Press release 📈 Stocks 🌍 United States

Viking Therapeutics Shares New VENTURE Trial Data for Obesity Drug VK2735

Viking Therapeutics reported that 74% of patients in its Phase 2 VENTURE trial for VK2735 achieved at least one BMI category improvement after 13 weeks, alongside positive shifts in key cardiometabolic health markers.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: VKTX → 2/10 (65% confidence).

📊 Affected Assets (1)

VKTX
Neutral 🤖 65%
⚡ Intraday 🌍 US · Explicit

An exploratory post-hoc analysis of the already-reported Phase 2 VENTURE trial shows 74% of subcutaneous VK2735 patients improved by at least one BMI category versus 15% on placebo, with improvements in blood pressure, lipids, glucose and waist circumference after 13 weeks. This supports the obesity franchise narrative but adds no new trial data, guidance or milestone beyond previously announced 14.7% weight-loss results, so it is supportive context rather than a material change in outlook.

🧭 Full analysis of these assets

🎯 Key Takeaways

  • 74% of participants receiving subcutaneous VK2735 improved by at least one BMI category after 13 weeks, versus 15% on placebo.
  • VK2735-treated patients showed greater reductions in waist circumference, blood pressure, glucose, and lipids compared to those with no BMI category change.
  • Viking also presented baseline characteristics for its ongoing Phase 3 VANQUISH-2 study, which is expected to be completed in 2027.
  • Previous VENTURE trial results showed up to 14.7% mean body weight reduction after 13 weeks of treatment.

📝 Executive Summary

Viking Therapeutics presented new exploratory data from its Phase 2 VENTURE trial at ObesityWeek 2026. The analysis revealed that 74% of participants treated with subcutaneous VK2735 improved by at least one BMI category after 13 weeks, compared to 15% for the placebo group. These patients also showed significant improvements in cardiometabolic markers, including blood pressure, glucose, and waist circumference.